- Home
- ARVN
ARVN
Arvinas Inc.
as 10-17-2024 4:00pm EST
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 1.7B | IPO Year: | 2018 |
| Target Price: | $57.50 | AVG Volume (30 days): | 562.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.57 - $53.08 | Next Earning Date: | 11-05-2024 |
| Revenue: | $93,300,000 | Revenue Growth: | -40.99% |
| Revenue Growth (this year): | 179.49% | Revenue Growth (next year): | -8.00% |
Latest Arvinas Inc. News
ARVN Breaking Stock News: Dive into ARVN Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Arvinas (NASDAQ:ARVN) shareholders have endured a 74% loss from investing in the stock three years ago
GuruFocus.com
a month ago
Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares
Insider Monkey
a month ago
Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now
GlobeNewswire
2 months ago
Arvinas to Participate in Upcoming Investor Conferences
Simply Wall St.
2 months ago
Brokers Are Upgrading Their Views On Arvinas, Inc. (NASDAQ:ARVN) With These New Forecasts
Simply Wall St.
3 months ago
Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
MT Newswires
3 months ago
Oppenheimer Adjusts Arvinas Price Target to $50 From $70, Maintains Outperform Rating
MT Newswires
3 months ago
Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO
Compare ARVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARVN Arvinas Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.